Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Anastrozole
×
Overview
What is Anastrozole?
Anastrozole tablets for oral administration contain 1 mg of anastrozole, a
non-steroidal aromatase inhibitor. It is chemically described as
1,3-Benzenediacetonitrile, a, a, a’,
a’-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl). Its molecular formula is
C17H19N5 and its structural formula is:
Anastrozole is an off-white powder with a molecular weight of 293.4.
Anastrozole has moderate aqueous solubility (0.5 mg/mL at 25°C); solubility is
independent of pH in the physiological range. Anastrozole is freely soluble in
methanol, acetone, ethanol, and tetrahydrofuran, and very soluble in
acetonitrile.
Each tablet contains as inactive ingredients: lactose
monohydrate, magnesium stearate, hypromellose, polyethylene glycol, povidone,
sodium starch glycolate and titanium dioxide.
What does Anastrozole look like?
What are the available doses of Anastrozole?
3
What should I talk to my health care provider before I take Anastrozole?
Enter section text here
How should I use Anastrozole?
Enter section text here
Enter section text here
What interacts with Anastrozole?
Sorry No Records found
What are the warnings of Anastrozole?
Sorry No Records found
What are the precautions of Anastrozole?
Sorry No Records found
What are the side effects of Anastrozole?
Sorry No records found
What should I look out for while using Anastrozole?
Enter section text here
What might happen if I take too much Anastrozole?
Clinical trials have been conducted with anastrozole tablets, up to 60 mg in
a single dose given to healthy male volunteers and up to 10 mg daily given to
postmenopausal women with advanced breast cancer; these dosages were tolerated.
A single dose of anastrozole tablets that results in life-threatening symptoms
has not been established. There is no specific antidote to overdosage and
treatment must be symptomatic. In the management of an overdose, consider that
multiple agents may have been taken. Vomiting may be induced if the patient is
alert. Dialysis may be helpful because anastrozole tablets are not highly
protein bound. General supportive care, including frequent monitoring of vital.
signs and close observation of the patient, is indicated.
How should I store and handle Anastrozole?
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].Keep out of reach of children.Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].Keep out of reach of children. These tablets are supplied inStorage These tablets are supplied inStorage
×
Clinical Information
Chemical Structure
No Image found
Clinical Pharmacology
The growth of many cancers of the breast is stimulated or maintained by
estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e.,
estrogen and/or progesterone receptor positive or receptor unknown) has included
a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy,
hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational
agents). These interventions lead to decreased tumor mass or delayed progression
of tumor growth in some women.
In postmenopausal women, estrogens are
mainly derived from the action of the aromatase enzyme, which converts adrenal
androgens (primarily androstenedione and testosterone) to estrone and estradiol.
The suppression of estrogen biosynthesis in peripheral tissues and in the cancer
tissue itself can therefore be achieved by specifically inhibiting the aromatase
enzyme.
Anastrozole is a potent and selective non-steroidal aromatase
inhibitor. It significantly
Non-Clinical Toxicology
Enter section text here
The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators. Alcohol, in particular, has been found to exhibit additive effects of this variety.
Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. Dose adjustments of either class of agents may be necessary.
Enter section text here
Serious adverse reactions with anastrozole tablets occurring in less than 1 in
10,000 patients, are: 1) skin reactions such as lesions, ulcers, or blisters; 2)
allergic reactions with swelling of the face, lips, tongue, and/or throat. This
may cause difficulty in swallowing and/or breathing; and 3) changes in blood
tests of the liver function, including inflammation of the liver with symptoms
that may include a general feeling of not being well, with or without jaundice,
liver pain or liver swelling .
Common adverse reactions (occurring with an
incidence of >10%) in women taking anastrozole tablets included: hot flashes,
asthenia, arthritis, pain, arthralgia, pharyngitis, hypertension, depression,
nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, pain,
headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis and
lymphedema.
In the ATAC trial, the most common reported adverse reaction
(>0.1%) leading to discontinuation of therapy for both treatment groups was
hot flashes, although there were fewer patients who discontinued therapy as a
result of hot flashes in the anastrozole tablets group.
Because clinical
trials are conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a drug cannot be directly compared to rates
in the clinical trials of another drug and may not reflect the rates observed in
practice.
×
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Clonazepam Description
Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake.
Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula:
C15H10ClN3O3 M.W. 315.72
×
Tips
Tips
×
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib).
228 major drug interactions (854 brand and generic names)
210 moderate drug interactions (691 brand and generic names)
2 minor drug interactions (4 brand and generic names)
Show all medications in the database that may interact with Imbruvica (ibrutinib).
